Sanofi Consumer Healthcare India: Q1CY26 Profit Up 36%

The key takeaway from Q1CY26

Sanofi Consumer Healthcare India Ltd. reported a mixed top-line trend in Q1CY26, with sequential softness but strong year-on-year growth. Revenue from operations fell quarter-on-quarter, while profitability improved modestly versus the previous quarter and rose sharply compared with the year-ago period. The company’s results also sit alongside a broader set of disclosures around the demerger from Sanofi India Limited, dividend recommendations, and corporate events.

The data points in the latest quarter provide a clearer view of performance after the company became a standalone consumer healthcare entity. Management commentary and earlier quarterly updates also highlight the role of domestic growth, exports off a low base, and product launches.

Q1CY26: headline financial numbers

For Q1CY26, revenue from operations stood at Rs 2,292 million. This was down 8.69% quarter-on-quarter from Rs 2,510 million in Q4CY25, but up 32.79% year-on-year from Rs 1,726 million in Q1CY25. Total income for Q1CY26 came in at Rs 2,348 million, compared with Rs 2,556 million in Q4CY25 and Rs 1,778 million in Q1CY25.

On the profit line, profit before tax (PBT) was Rs 907 million in Q1CY26, marginally higher than Rs 905 million in Q4CY25 and up from Rs 668 million in Q1CY25. Net profit for the period was Rs 678 million, up from Rs 665 million in the preceding quarter and Rs 500 million in the year-ago quarter.

Revenue and income: sequential decline, strong YoY growth

The sequential decline in Q1CY26 revenue and total income is visible across both key top-line measures reported by the company. Revenue from operations decreased from Rs 2,510 million in Q4CY25 to Rs 2,292 million in Q1CY26. Total income also eased from Rs 2,556 million to Rs 2,348 million over the same period.

However, the year-on-year comparison remains strong. Revenue from operations expanded from Rs 1,726 million in Q1CY25 to Rs 2,292 million in Q1CY26, and total income rose from Rs 1,778 million to Rs 2,348 million. The company’s earlier updates have repeatedly flagged the impact of exports off a low base and product initiatives, which provides context for the sharp YoY movement.

Profitability: PBT and PAT hold up despite softer revenue

While revenue dipped sequentially, Q1CY26 profitability remained resilient. PBT increased slightly to Rs 907 million from Rs 905 million in Q4CY25 and rose 35.78% YoY from Rs 668 million in Q1CY25. Net profit for the period climbed to Rs 678 million from Rs 665 million in Q4CY25 and increased 35.60% YoY from Rs 500 million.

Total comprehensive income in Q1CY26 was also Rs 678 million, compared with Rs 651 million in Q4CY25 and Rs 500 million in Q1CY25. The quarter’s numbers indicate that profit growth outpaced revenue growth on a year-on-year basis.

EPS trend in Q1CY26

Earnings per share (EPS) in Q1CY26 was Rs 29.44. This compared with Rs 28.87 in Q4CY25 and Rs 21.69 in Q1CY25. The EPS movement is consistent with the reported growth in net profit over the same periods.

Context from Q4CY25 and other quarterly updates

The company’s Q4CY25 snapshot included revenue of Rs 2,510 million, described as a growth of 47% (as stated in the update). The same update said domestic sales grew by 23% and export sales grew by 9.3x due to a low base. Profit after tax for Q4CY25 was reported at Rs 665 million, an increase of 50% on a YoY basis.

Separately, in a Q2CY25 result update, the company reported revenue of Rs 2,209 million, a 28% YoY increase. Profit after tax for that quarter was Rs 607 million, and the company also reported sales growth of 27.5% from Q1CY25.

In another quarterly note titled Q2FY26, Sanofi Consumer Healthcare India reported revenue of Rs 2,339 million (growth of 46%), domestic sales growth of 20%, export sales growth of more than 10X due to a low base, and profit after tax up by 40%. The same note carried a comment from Managing Director Himanshu Bakshi that referred to “third-quarter results,” as stated in the text.

Demerger and comparability note

Sanofi Consumer Healthcare India noted that certain quarterly and half-year numbers are not directly comparable due to the demerger from Sanofi India Limited and the voluntary recall of certain product variants. The demerger became effective on June 1, 2024, creating Sanofi Consumer Healthcare India Limited as a separate legal entity focused on the consumer healthcare segment.

This context is relevant when reading growth rates and changes across periods that span pre- and post-demerger timelines.

Half-year datapoints and cash flow disclosure

For the half-year ended June 30, 2025, the company disclosed profit after tax of Rs 1,107 million and sales of products at Rs 3,935 million. It also reported net cash flow from operations of Rs 179 million during the half year ended June 30, 2025, down from Rs 2,315 million in the same period last year.

These figures were presented alongside the company’s comment that comparability was affected by the demerger and a voluntary recall of certain variants.

Dividend, AGM updates, and audit opinions

In disclosures around the year ended December 31, 2025, the company stated that auditors issued an unqualified audit report on the annual accounts. The company also said revenue from operations increased by 21% to Rs 8,784 million, and profit after tax grew by 33% versus the prior year. It further reported return on capital employed (ROCE) at 62.5% and referenced EBITDA at 36%.

The board recommended a final dividend of INR 75 per equity share for the financial year ended December 31, 2025, compared with INR 55 per share in the previous year (as stated). For the financial year ended December 31, 2024, the company had recommended a final dividend of Rs 55 per equity share (face value Rs 10), subject to shareholder approval.

The company’s 3rd Annual General Meeting was held on June 26, 2026. The dividend payment date mentioned in the AGM-related schedule was Thursday, July 9, 2026.

Stock reaction referenced in earlier results

The text also noted a sharp market reaction around Q2 2025 results, stating that Sanofi Consumer Healthcare India surged 12.56% to Rs 5,385 after announcing strong financial results for the second quarter of 2025. The same update repeated the Q2 2025 revenue and profit figures and again highlighted that financials were not strictly comparable due to the demerger and voluntary recall of certain variants.

Key numbers at a glance

Why these updates matter for investors tracking the consumer health space

The Q1CY26 numbers show that earnings remained steady even as revenue softened sequentially. For investors, this combination typically draws attention to mix, cost control, and the sustainability of growth drivers cited in earlier quarters such as exports off a low base and new launches.

At the same time, the company has repeatedly flagged the impact of structural changes. The demerger effective June 1, 2024 and the voluntary recall of certain product variants were explicitly cited as reasons why quarter and half-year comparisons may not be straightforward.

What to watch next

Sanofi also referenced an investor-facing event, stating that second quarter 2026 results would be reviewed by management during a live audio webcast with the financial community on July 30, 2026, followed by a Q&A session.

For near-term monitoring, investors are likely to focus on whether revenue returns to sequential growth after Q1CY26’s decline, and how management frames comparability and operating performance in subsequent updates.